[go: up one dir, main page]

MX2010003695A - Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento. - Google Patents

Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento.

Info

Publication number
MX2010003695A
MX2010003695A MX2010003695A MX2010003695A MX2010003695A MX 2010003695 A MX2010003695 A MX 2010003695A MX 2010003695 A MX2010003695 A MX 2010003695A MX 2010003695 A MX2010003695 A MX 2010003695A MX 2010003695 A MX2010003695 A MX 2010003695A
Authority
MX
Mexico
Prior art keywords
carboxyl
drug
heavy chain
sequence encoding
tetanus toxin
Prior art date
Application number
MX2010003695A
Other languages
English (en)
Inventor
Maria Moreno Igoa
Ana Cristina Calvo Royo
Ma Jesus Munoz Gonzalvo
Ma Pilar Zaragoza Fernandez
Jose Aguilera Avila
Rosario Ostas Pinzolas
Original Assignee
Univ Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zaragoza filed Critical Univ Zaragoza
Publication of MX2010003695A publication Critical patent/MX2010003695A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al uso de la secuencia codificante del domino del extremo carboxilo terminal de la cadena pesada de la toxina tetánica como medicamento, preferentemente en el tratamiento de la Esclerosis Lateral Amiofrófica (ELA), así como el polipéptido codificado por dicha secuencia para el tratamiento de la mencionada enfermedad.
MX2010003695A 2007-10-05 2008-10-03 Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento. MX2010003695A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200702621A ES2332628B1 (es) 2007-10-05 2007-10-05 Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento.
PCT/ES2008/070186 WO2009043963A1 (es) 2007-10-05 2008-10-03 Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetánica como medicamento

Publications (1)

Publication Number Publication Date
MX2010003695A true MX2010003695A (es) 2010-09-14

Family

ID=40525852

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003695A MX2010003695A (es) 2007-10-05 2008-10-03 Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento.

Country Status (10)

Country Link
US (2) US8945586B2 (es)
EP (1) EP2210611B1 (es)
JP (1) JP5325224B2 (es)
CN (1) CN101873865B (es)
BR (1) BRPI0817792A2 (es)
CA (1) CA2701521C (es)
ES (2) ES2332628B1 (es)
MX (1) MX2010003695A (es)
RU (1) RU2495676C2 (es)
WO (1) WO2009043963A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332628B1 (es) 2007-10-05 2011-01-24 Universidad De Zaragoza Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento.
US20170151316A1 (en) * 2014-07-02 2017-06-01 Spherium Biomed, S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
ATE352558T1 (de) * 1997-08-14 2007-02-15 Pasteur Institut Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren
EP1365800B1 (en) * 2000-06-28 2013-03-06 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US20060246036A1 (en) * 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
ES2281278B1 (es) * 2006-01-20 2008-10-16 Universidad Autonoma De Barcelona Empleo de un polipeptido que comprende el dominio c-terminal de la cadena pesada de la toxina tetanica en el tratamiento del parkinsonismo.
WO2008094583A2 (en) * 2007-01-30 2008-08-07 The General Hospital Corporation Methods and devices for mri-based measurement of axonal transport in vivo and delivery of therapeutic substances to the cns
ES2332628B1 (es) 2007-10-05 2011-01-24 Universidad De Zaragoza Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento.

Also Published As

Publication number Publication date
RU2495676C2 (ru) 2013-10-20
CN101873865B (zh) 2013-06-05
JP2010540599A (ja) 2010-12-24
US8945586B2 (en) 2015-02-03
CA2701521A1 (en) 2009-04-09
WO2009043963A1 (es) 2009-04-09
US20160017008A1 (en) 2016-01-21
CN101873865A (zh) 2010-10-27
RU2010115135A (ru) 2011-11-10
US20100261656A1 (en) 2010-10-14
EP2210611A1 (en) 2010-07-28
JP5325224B2 (ja) 2013-10-23
ES2463770T3 (es) 2014-05-29
CA2701521C (en) 2015-12-01
ES2332628A1 (es) 2010-02-09
BRPI0817792A2 (pt) 2015-03-24
ES2332628B1 (es) 2011-01-24
EP2210611A4 (en) 2010-12-15
EP2210611B1 (en) 2014-02-26

Similar Documents

Publication Publication Date Title
BE2021C505I2 (es)
MY163119A (en) Use of tenecteplase for treating acute ischemic stroke
MY156667A (en) Disubstituted phthalazine hedgehog pathway antagonists
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
MY156315A (en) Anti-vegf antibodies
PH12013500356A1 (en) Engineered anti-tslp antibody
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2012006553A (es) Anticuerpos contra csf-1r humano y usos de los mismos.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
SG170086A1 (en) Modified molecules which promote hematopoiesis
EP3988673A3 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
ATE532814T1 (de) Neue ammonium-polyurethan- und/oder polycarbonat- verbindungen
MA32935B1 (fr) Agent prophylactique/therapeutique pour le cancer
MX2011010634A (es) Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa.
EA201000433A1 (ru) Лечение вазомоторных симптомов
MX2010003695A (es) Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento.
MX2009005117A (es) Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.
WO2010004031A3 (en) Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
MX2009007054A (es) Uso terapeutico novedoso para tratar leucemia.
TW200744577A (en) Method for treating osteoarthritis
PL2036575T3 (pl) Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością

Legal Events

Date Code Title Description
FG Grant or registration